Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript

Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM

Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts

Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Journey Medical Corporation (NASDAQ:DERM) Receives $12.17 Consensus Target Price from Brokerages

Financial Review: Zevra Therapeutics (NASDAQ:ZVRA) versus Journey Medical (NASDAQ:DERM)

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript

Compared to Estimates, Journey Medical (DERM) Q3 Earnings: A Look at Key Metrics

Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Brighton Jones LLC Lowers Stock Holdings in Journey Medical Corporation $DERM

Focus Partners Advisor Solutions LLC Acquires Shares of 10,000 Journey Medical Corporation $DERM

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Journey Medical Corporation to Participate in October 2025 Investor Conferences

Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon

New Strong Sell Stocks for September 4th

Journey Medical Corporation to Participate in September 2025 Investor Conferences

Journey Medical Corporation to Present at the Emerging Growth Conference

CoreWeave, CAVA Group, Journey Medical And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript

Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates

Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11

Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™

Journey Medical to Join Russell 2000® and Russell 3000® Indexes

Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference

Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV

Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript

Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates